

AD _____

MIPR NUMBER 93MM3506

TITLE: Interphase Cytogenetics in Breast Tumors P53 Gene
Alterations

PRINCIPAL INVESTIGATOR: Isabell A. Sesterhenn, M.D.

CONTRACTING ORGANIZATION: Armed Forces Institute of Pathology
Washington, DC 20306-6000

REPORT DATE: October 1993

TYPE OF REPORT: Midterm

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19980423 030

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Service, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.</small>				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1993		3. REPORT TYPE AND DATES COVERED Midterm (27 Oct 92 - 30 Sep 93)
4. TITLE AND SUBTITLE Interphase Cytogenetics in Breast Tumors P53 Gene Alterations				5. FUNDING NUMBERS 93MM3506
6. AUTHOR(S) Sesterhenn, Isabell A, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Armed Forces Institute of Pathology Washington, DC 20306-6000				8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 words) PURPOSE: To compare numerical chromosome aberrations and p53 gene alterations in 250 node-negative breast cancers to 250 non-positive breast cancers and their survival. SCOPE: Interphase cytogenetics will be performed in paraffin sections utilizing biotinylated probes specific for centromeric regions of chromosomes 1, 8, 11, 13, 17, 18, and X. Chromosome profiles based on 300 tumor cells will be generated for each patient. Serial sections of the same paraffin blocks will be utilized to assess p53 alterations immunohistochemically. If present, further amplification and sequencing of p53 gene will be done utilizing PCR denaturing gel gradient electrophoresis and coupled amplification and sequencing protocols. MAJOR FINDINGS: Preliminary analysis showed there was a statistically significant increase in the copy numbers of chromosome 1 with nuclear grade. Similarly, increasing numbers of chromosome 18 were observed with increase in nuclear grade. However, there was no significant increase in the copy numbers of chromosomes 8, 11, 13/21, 17 and X when correlated with nuclear grade. All of them showed extra copies in nuclear grade I, II, and III tumors. Comparison of copy numbers of the different chromosomes in tumor to normal epithelial cells showed a gain for chromosomes 8, 11, 13/21, 17, and X. However, in individual cases, loss of chromosome 17 and X chromosome was encountered.				
14. SUBJECT TERMS Breast Cancer				15. NUMBER OF PAGES
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

2.S. For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

2. Selwyn
PI - Signature

13. Nov 97
Date

Table of Contents

Cover	1
SF 298	2
Foreword	3
Table of Contents	4
Purpose	5
Scope	5
Major Findings	5

MID-TERM REPORT - 93MM3506

TITLE OF PROPOSAL: Interphase Cytogenetics in Breast Tumors p53 Gene Alterations.

PRINCIPAL INVESTIGATOR: Isabell A. Sesterhenn, M.D.

Ref.: DD Form 448, Amendment received [dated 12/10/96] extending proposal period until 30 JUNE 1998.

PURPOSE: To compare numerical chromosome aberrations and p53 gene alterations in 250 node-negative breast cancers to 250 non-positive breast cancers and their survival. Although conventional cytogenetic analysis has been successful only in about 50 breast cancers, it has been helpful in identification of subtypes of ductal carcinomas. Since cytogenetic equivalents for gene amplification are net gain of chromosomal material and for loss of heterozygosity are net loss of chromosomal material or structural aberrations, we believe that interphase cytogenetics may be helpful in subclassification of ductal carcinomas. P53 gene alterations may prove to be an early event in breast cancer progression.

SCOPE: Interphase cytogenetics will be performed in paraffin sections utilizing biotinylated probes specific for centromeric regions of chromosomes 1, 8, 11, 13, 17, 18, and X. -Chromosome profiles based on 300 tumor cells will be generated for each patient. Serial sections of the same paraffin blocks will be utilized by Dr. O'Leary to assess p53 alterations immunohistochemically. If present, further amplification and sequencing of p53 gene will be done utilizing PCR denaturing gel gradient electrophoresis and coupled amplification and sequencing protocols. The data will be analyzed by the Kaplan-Meyer and Cox proportional hazards model, comparing the two groups of patients. Pathology Data Division is follow-up in progress.

MAJOR FINDINGS: Two hundred ninety-two cases have been completed. An additional 78 cases are close to completion. Pathology Data Division follow-up is in progress.

Preliminary analysis of 37 node-negative tumors, statistical analysis was performed. The Jonckheere-Terpstra test (Hollander & Wolfe, 1973) was used to determine if the chromosomal spot counts were identically distributed in each grade considered. In addition, the standardized Jonckheere-Terpstra test statistics allow one to determine the relationship between chromosomal spot counts and grade. Two-sided asymptotic p-values were determined. Integer values were used for each chromosomal spot count. The Jonckheere-Terpstra test was also used to compare normal tissue chromosomal spot counts to tumor chromosomal spot counts, with both tissues coming from the same biopsy.

Comparison of the chromosomal profiles to the tumor grade as determined by the Bloom and Richardson methods modified by Elston

did not show any correlation. However, if the tumors were grouped according to the nuclear grade, there was a statistically significant increase in the copy numbers of chromosome 1 with nuclear grade. Similarly, increasing numbers of chromosome 18 were observed with increase in nuclear grade. However, there was no significant increase in the copy numbers of chromosomes 8, 11, 13/21, 17 and X when correlated with nuclear grade. All of them showed extra copies in nuclear grade I, II, and III tumors. Comparison of copy numbers of the different chromosomes in tumor to normal epithelial cells showed a gain for chromosomes-8, 11, 13/21, 17, and X. However, in individual cases, loss of chromosome 17 and X chromosome was encountered.

p53 analysis is in progress.